Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79


Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.

Podsypanina K, Politi K, Beverly LJ, Varmus HE.

Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5242-7. doi: 10.1073/pnas.0801197105. Epub 2008 Mar 20.


Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.

Jang JW, Boxer RB, Chodosh LA.

Mol Cell Biol. 2006 Nov;26(21):8109-21. Epub 2006 Aug 14.


NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.

Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.

Int J Cancer. 2013 Jan 1;132(1):9-18. doi: 10.1002/ijc.27644. Epub 2012 Jun 13.


Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY.

Neoplasia. 2014 Sep;16(9):757-69. doi: 10.1016/j.neo.2014.08.003.


Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.

Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B Jr, Heeschen C.

Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.


c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA.

Nat Med. 2001 Feb;7(2):235-9.


The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.

Aprelikova O, Chen K, El Touny LH, Brignatz-Guittard C, Han J, Qiu T, Yang HH, Lee MP, Zhu M, Green JE.

Clin Epigenetics. 2016 Apr 14;8:38. doi: 10.1186/s13148-016-0205-6. eCollection 2016.


Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.

Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ.

Ann Surg. 1995 Jun;221(6):706-18; discussion 718-20.


Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.

Figueiredo ML, Stein TJ, Jochem A, Sandgren EP.

Liver Int. 2012 Apr;32(4):582-91. doi: 10.1111/j.1478-3231.2011.02732.x. Epub 2012 Jan 3.


DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.

Weng TY, Yen MC, Huang CT, Hung JJ, Chen YL, Chen WC, Wang CY, Chang JY, Lai MD.

Gene Ther. 2014 Oct;21(10):888-96. doi: 10.1038/gt.2014.67. Epub 2014 Jul 31.


Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.


Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.

Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, Wang J, Zhang J.

J Biol Chem. 2013 Jun 21;288(25):18219-27. doi: 10.1074/jbc.M113.475376. Epub 2013 May 14. Erratum in: J Biol Chem. 2013 Dec 27;288(52):37368.


Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.

Cleary AS, Leonard TL, Gestl SA, Gunther EJ.

Nature. 2014 Apr 3;508(7494):113-7. doi: 10.1038/nature13187.


Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.

Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW.

PLoS One. 2008 May 7;3(5):e2125. doi: 10.1371/journal.pone.0002125.


Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.

Parikh N, Shuck RL, Nguyen TA, Herron A, Donehower LA.

Mol Cancer Res. 2012 Jun;10(6):845-55. doi: 10.1158/1541-7786.MCR-12-0089. Epub 2012 Apr 24.


KRAS Engages AGO2 to Enhance Cellular Transformation.

Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, Kumar-Sinha C, Chinnaiyan AM.

Cell Rep. 2016 Feb 16;14(6):1448-61. doi: 10.1016/j.celrep.2016.01.034. Epub 2016 Feb 4.


Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.

Cho HC, Lai CY, Shao LE, Yu J.

Cancer Res. 2011 Dec 1;71(23):7250-8. doi: 10.1158/0008-5472.CAN-11-0903. Epub 2011 Nov 16.


Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.


Supplemental Content

Support Center